TechAmerica
SearchSubscribe

Spectris AD

1 article

Spectris AD, newest first

  1. Cognito Alzheimer’s Trial Misses Primary Endpoint
    Biotech & Health

    Cognito Alzheimer’s Trial Misses Primary Endpoint

    Cognito’s Phase 3 HOPE study missed its primary endpoint. Findings in a prespecified mild-disease subgroup suggest possible benefit, but Spectris AD remains investigational as the company prepares for FDA discussions.

    By Keshav Khandelwal4 min read

Newsletters

The day's tech news, in five minutes

Written by the reporters who cover each beat. No sponsored stories, and you can unsubscribe in one click.

Send me

By subscribing you agree to our Terms and Privacy policy.

Thank you

Your newsletter subscription has been received. Thank you for subscribing to TechAmerica.ai.